[ANTENATAL APPLICATION OF CORTICOSTEROIDS IN LATE PRETERM BIRTHS]

Akusherstvo I Ginekologiia
|August 13, 2016
PubMed

Insights

Antenatal corticosteroid therapy is recommended for women at risk of premature birth. However, its benefits after 34 weeks of gestation remain under discussion.

Area of Science:

  • Obstetrics and Gynecology
  • Neonatal Medicine
  • Pharmacology

Context:

  • Premature birth presents significant risks to neonates.
  • Antenatal corticosteroid (ACS) administration is a key intervention to improve neonatal outcomes.
  • Evidence regarding the efficacy and safety of ACS after 34 weeks of gestation is evolving.

Purpose:

  • To review and synthesize current evidence on the antenatal use of corticosteroids in the context of premature birth.
  • To critically evaluate the benefits and risks of corticosteroid administration between 34 and 37 weeks of gestation.
  • To inform clinical practice guidelines and future research directions.

Summary:

  • Current evidence supports the use of antenatal corticosteroids for women at risk of preterm birth before 34 weeks gestation.
  • The benefits of antenatal corticosteroids in women at risk of preterm birth after 34 weeks gestation are less clear and subject to ongoing debate.
  • Further research is needed to establish optimal timing and protocols for corticosteroid use in late preterm infants.

Impact:

  • Provides a comprehensive overview of the current evidence base for antenatal corticosteroid use.
  • Highlights areas of uncertainty and controversy, particularly for late preterm births.
  • Aims to guide clinical decision-making and resource allocation in perinatal care.

Related Concept Videos

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
1.8K
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
598
Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
4.4K
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
1.1K
Intrauterine Drug Delivery Systems01:21

Intrauterine Drug Delivery Systems

Controlled-release systems for intravaginal and intrauterine drug delivery have been developed primarily for the administration of contraceptive steroid hormones. These delivery routes circumvent first-pass hepatic metabolism, thereby enhancing bioavailability and allowing for reduced systemic dosages compared to oral administration. Such approaches contribute to improved therapeutic efficacy and patient compliance, particularly in long-term contraceptive regimens.Intravaginal Drug Delivery...
101